Secondary hormonal therapy for prostate cancer: What lies on the horizon?

BJU International

Volumn 101, Issue 3, 2008, Pages 271-274

  Sharifi, Nima ^a   Dahut, William L ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANDROSTENEDIONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BMS 641988; COLCHICINE; COLCHICINE CYANONILUTAMIDE; CYPROTERONE ACETATE; CYTOTOXIC AGENT; ESTROGEN RECEPTOR; FLUTAMIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYDROXYFLUTAMIDE; KETOCONAZOLE; MEGESTROL ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TANESPIMYCIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION; HUMAN; HYPERTENSION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; WITHDRAWAL SYNDROME; X RAY CRYSTALLOGRAPHY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FORECASTING; HEAT-SHOCK PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, STEROID; STEROIDS;

EID: 37849000456     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07236.x     Document Type: Short Survey

References (21)

1. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 17 : 3461 7
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005 294 : 238 44
3. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine Rev 2004 25 : 276 308
4. Mostaghel EA, Montgomery RB, Lin DW. The basic biochemistry and molecular events of hormone therapy. Current Urol Reports 2007 8 : 224 32
5. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a Cancer and Leukemia Group B study. Clin Cancer Res 2007 13 : 2030 7
6. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nature (Clin Prac) 2007 4 : 236 44
7. Anonymous. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000 355 : 1491 8
8. Sharifi N, Farrar WL. Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Therap 2006 13 : 166 70
9. Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol 2006 176 : S66 71
10. Ryan CJ, Rosenberg J, Lin A, Valiente J, Kim J, Small EJ. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-lyase inhibitor in androgen-independent prostate cancer (AIPC). Proceedings of the American Society of Clinical Oncology, Chicago 2007
11. Attard G, Yap TA, Reid AH et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (a), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. Proceedings of the American Society of Clinical Oncology, Chicago 2007
12. Figg WD, Sartor O, Cooper MR et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995 98 : 412 4
13. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993 149 : 607 9
14. Veldscholte J, Ris-Stalpers C, Kuiper GG et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Comms 1990 173 : 534 40
15. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005 102 : 6201 6
16. Salvati ME, Balog A, Wei DD et al. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3 (2H)-dione nucleus. Bioorganic Med Chem Lett 2005 15 : 389 93
17. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002 277 : 26321 6
18. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science (New York, NY) 1998 279 : 1922 5
19. Fletterick RJ. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer. BJU Int 2005 96 (Suppl. 2 2 9
20. Sharifi N, Hamel E, Lill MA et al. A bifunctional colchicinoid that binds to the androgen receptor. Molecular Canc Ther 2007 6 : 2328 36
21. Wang LH, Yang XY, Zhang X et al. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006 10 : 487 99